The 6 linked references in paper E. PANCHENKO P., Е. ПАНЧЕНКО П. (2017) “ИЗМЕНИЛИСЬ ЛИ НАШИ ПРЕДСТАВЛЕНИЯ О НЕОБХОДИМОСТИ КЛОПИДОГРЕЛА В ЛЕЧЕНИИ КАРДИОЛОГИЧЕСКИХ БОЛЬНЫХ С ПОЯВЛЕНИЕМ БОЛЕЕ МОЩНЫХ АНТИАГРЕГАНТОВ? // HAVE WE SHIFTED OUR PARADIGM OF CLOPIDOGREL AS A MANDATORY DRUG IN TREATMENT OF CARDIOLOGICAL PATIENTS AFTER THE INTRODUCTION OF MORE POWERFUL ANTIAGREGANTS?” / spz:neicon:aterotromboz:y:2017:i:2:p:32-42

  1. Udell JA, Bonaca M, Collet J-Ph et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: acollaborative meta-analysis of randomized trials. Eur Heart Journal, doi:10.1093/eurheartj/ehv443.
  2. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation. doi:10.1093/eurheartj/ehx393.
  3. 2017 ESC fosed update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. doi:10.1093/eurheartj/ehx419.
  4. Biscaglia S, Campo G, Pavasini R et al. Occurrence, causes and outcome after switching from ticagrelor to clopidogrel in real-life scenario: data from a prospective registry. Platelets, 2016. Doi:10.3109/09537104.2015.1119815.
  5. Cuisset T, Deharo P, Quilici J et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart Journal,2017. doi:10.1093/eurheartj/ehx175.
  6. International Expert Consensus on Switching Platelet P2Y12Receptor — Inhibiting Therapies. Circulation, 2017, 136: 00–00. DOI: 10.1161/CIRCULATIONAHA.117.031164.